HIV i-Base

March/April HTB now online


CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments…

CROI 2014: early reports


First reports from CROI 2014: no linked HIV transmissions when viral load is suppressed; 3-monthly PrEP injections, PI/r monotherapy, ACTG 5257, NEAT001, paediatric ARV pipeline, low dose efavirenz and more…

January/February HTB now online

Women and HIV, research update on HIV persistence and cure, sofosbuvir approved for hepatitis C in the US and Europe, priced at $1000 a day…

November/December HTB now online

TB treatment for children, reports from EACS, global funding for treatment, efavirenz and risk of suicide, i-Base job vacancies…

i-Base job vacancy for treatment advocate

i-Base have a vacancy for a new advocate to join the team. We also are looking at freelance writers to contribute to HIV Treatment Bulletin. Full details.

Elvitegravir positive opinion in Europe

NOTE: EU granted full approval for elvitegravir on 18 November 2013. ……………… On 19 September 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation in Europe for the integrase inhibitor elvitegravir 85 …

September/October HTB now online

ICAAC and IAS conferences; CROI archive website still blocked; cobicistat approved in the EU, Stribild in England, dolutegravir in the US – and pricing in the UK and globally…

July/August HTB now online

Over 20 reports from three leading conferences: 7th IAS conference, 5th Paediatric Workshop and International Drug Resistance Workshop. Plus phasing out d4T, plans for new tenofovir and where is the CROI website?

Post navigation